Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND AND HYPOTHESIS: The predictive value of specific markers of infection and autoimmunity for coronary events, such as the effects of statins on inflammation, is still controversial. METHODS: A case-control design was used to compare C-reactive protein (CRP) levels, seropositivity for Chlamydia pneumoniae and Helicobacter pylori, and anti-oxidized low-density lipoprotein (oxLDL) antibody levels in prerandomization blood samples from 129 participants in the Scandinavian Simvastatin Survival Study who died (cases), and from 129 matched participants who were alive during 5-year follow-up (controls). RESULTS: Patients with CRP levels in the highest quartile had an increased risk of death compared with those in the first through third quartile (odds ratio [OR] = 2.51, 95% confidence interval [CI] 1.3-4.8). Seropositivity for Chlamydia pneumoniae or Helicobacter pylori and anti-oxLDL antibody levels were similar in cases and controls (p = NS). At a 4-month control, simvastatin reduced CRP levels (p = 0.009) while placebo did not (p = NS). However, the risk of death associated with high baseline CRP levels was similar in patients randomized to placebo (OR = 2.36, 95% CI 1.06-5.26) or simvastatin (OR = 3.13, 95% CI 1.06-9.21). CONCLUSIONS: Elevated CRP levels, but not seropositivity for Chlamydia pneumoniae or Helicobacter pylori, nor levels of anti-oxLDL antibodies, predict the risk of death in patients with stable ischemic heart disease. Simvastatin treatment reduces CRP levels, but without affecting the increased risk conferred by higher CRP levels at baseline.

Original publication

DOI

10.1002/clc.4960251005

Type

Journal article

Journal

Clinical cardiology

Publication Date

10/2002

Volume

25

Pages

461 - 466

Addresses

Istituto di Cardiologia, Università Cattolica, Rome, Italy. f.crea@flashnet.it

Keywords

Humans, Myocardial Ischemia, Simvastatin, Triglycerides, C-Reactive Protein, Biological Markers, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Treatment Outcome, Incidence, Risk Factors, Survival Analysis, Case-Control Studies, Follow-Up Studies, Seroepidemiologic Studies, Double-Blind Method, Predictive Value of Tests, Aged, Middle Aged, Scandinavia, Female, Male, Cholesterol, LDL, Hypolipidemic Agents